This was the first completed clinical trial evaluating MDMA for use in therapy.
The rate of clinical response (decrease in PTSD scale scores) for the MDMA (aka ecstasy) treatment group was 83% compared to 25% for the placebo group. The study found no serious adverse effects related to the treatment, also no adverse neurocognitive effects or significant increases in blood pressure.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.